{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:44:47Z","timestamp":1791229487399,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s10384-023-01024-4","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T06:02:26Z","timestamp":1697781746000},"page":"652-656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration"],"prefix":"10.1007","volume":"67","author":[{"given":"Taiichi","family":"Hikichi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"key":"1024_CR1","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"1024_CR2","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"1024_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43\u201358.","journal-title":"Am J Ophthalmol"},{"key":"1024_CR4","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SVR, Zhang K, Seven-Up Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292\u20139.","journal-title":"Ophthalmology"},{"key":"1024_CR5","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00417-019-04361-8","volume":"257","author":"I Wada","year":"2019","unstructured":"Wada I, Oshima Y, Shiose S, Kano K, Nakano S, Kaizu Y, et al. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients. Graefes Arch Clin Exp Ophthalmol. 2019;257:1411\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1024_CR6","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.oret.2020.03.010","volume":"4","author":"I Maruko","year":"2020","unstructured":"Maruko I, Ogasawara M, Yamamoto A, Itagaki K, Hasegawa T, Arakawa H, et al. Two-year outcomes of treat-and extend intravitreal aflibercept for exudative age-related macular degeneration. A prospective study. Ophthalmol Retina. 2020;4:767\u201376.","journal-title":"Ophthalmol Retina."},{"key":"1024_CR7","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and safety of intravitreal afliberecept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"key":"1024_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000003003","volume":"41","author":"JS Heier","year":"2021","unstructured":"Heier JS, Singh RP, Wykoff CC, Csaky KG, Lai TYY, Loewenstein A, et al. The angiopoietin\/Tie pathway in retinal vascular diseases. A review. Retina. 2021;41:1\u201319.","journal-title":"Retina."},{"key":"1024_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Ruiz CQ, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomized, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"1024_CR10","first-page":"2","volume":"A-120","author":"J Mitchell","year":"2007","unstructured":"Mitchell J, Brose LS, Bradley C. Design of a measure of satisfaction with treatment for macular degeneration (MacTSQ). Qual Life Res. 2007;A-120:2.","journal-title":"Qual Life Res"},{"key":"1024_CR11","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomized controlled trial. Lancet. 2013;382:1258\u201367.","journal-title":"Lancet"},{"key":"1024_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2021-000930","volume":"7","author":"TS Morken","year":"2022","unstructured":"Morken TS, Knutsen C, Hanseen MS, Austeng D. Patient satisfaction following a switch from treat-and-extend to observe-and-plan regimen in age-related macular degeneration. BMJ Open. 2022;7: e000930. https:\/\/doi.org\/10.1136\/bmjophth-2021-000930.","journal-title":"BMJ Open"},{"key":"1024_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13548506.2016.1274040","volume":"23","author":"J Boyle","year":"2018","unstructured":"Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23:127\u201340.","journal-title":"Psychol Health Med"},{"key":"1024_CR14","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00417-012-2177-3","volume":"251","author":"KM Droege","year":"2013","unstructured":"Droege KM, Muether PS, Hermann MM, Caramoy A, Viebahn U, Kirchof B, et al. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol. 2013;251:1281\u20134.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1024_CR15","first-page":"2695","volume":"260","author":"FG Holz","year":"2022","unstructured":"Holz FG, Schmitz-Valckenberg S, Wolf A, Agostini H, Lorenz K, Pielen A, et al. A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study. Graefes Arch Clin Exp Ophthalmol. 2022;260:2695\u2013702.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1024_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10384-022-00940-1","volume":"66","author":"Y Kitajima","year":"2022","unstructured":"Kitajima Y, Maruyama-Inoue M, Ikeda S, Ito A, Inoue T, Yanagi Y, et al. Short-term outcomes of switching to brolucizumab in Japanese patients with neovascular age-related macular degeneration. Jpn J Ophthalmol. 2022;66:511\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"1024_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ajo.2013.03.030","volume":"156","author":"Y Yonekawa","year":"2013","unstructured":"Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sorbin L, Eliot D, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156:29\u201325.","journal-title":"Am J Ophthalmol"},{"key":"1024_CR18","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.ophtha.2010.02.032","volume":"117","author":"OP Gupta","year":"2010","unstructured":"Gupta OP, Shienbaum G, Patel AH, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 2010;117:2134\u201340.","journal-title":"Ophthalmology"},{"key":"1024_CR19","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.2147\/OPTH.S395279","volume":"16","author":"RB Rush","year":"2022","unstructured":"Rush RB, Rush SW. Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2022;16:4041\u20136.","journal-title":"Clin Ophthalmol"},{"key":"1024_CR20","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2147\/OPTH.S409822","volume":"17","author":"EH Leung","year":"2023","unstructured":"Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Prez LI, et al. Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:1287\u201393.","journal-title":"Clin Ophthalmol"},{"key":"1024_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","volume":"144","author":"I Maruko","year":"2007","unstructured":"Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15\u201322.","journal-title":"Am J Ophthalmol"}],"updated-by":[{"DOI":"10.1007\/s10384-023-01035-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000}}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-023-01024-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-023-01024-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-023-01024-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T06:18:55Z","timestamp":1700201935000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-023-01024-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1024"],"URL":"https:\/\/doi.org\/10.1007\/s10384-023-01024-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10384-023-01035-1","asserted-by":"object"}]},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,20]]},"assertion":[{"value":"25 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10384-023-01035-1","URL":"https:\/\/doi.org\/10.1007\/s10384-023-01035-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T. Hikichi, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Chugai).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}